- Investing Ideas
- /
- U.S. Biotech Stocks
U.S. Biotech Stocks
Results
437
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
437 companies
Cumberland Pharmaceuticals
Market Cap: US$45.8m
A specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.
CPIX
US$3.03
7D
-8.6%
1Y
145.9%
CalciMedica
Market Cap: US$43.7m
A clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.
CALC
US$3.01
7D
-6.2%
1Y
-33.4%
Grace Therapeutics
Market Cap: US$42.9m
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
GRCE
US$3.08
7D
-1.3%
1Y
0.3%
Annovis Bio
Market Cap: US$42.7m
A clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
ANVS
US$2.13
7D
-9.4%
1Y
-74.2%
Century Therapeutics
Market Cap: US$42.1m
A clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
IPSC
US$0.49
7D
-3.8%
1Y
-68.1%
Lunai Bioworks
Market Cap: US$39.9m
A pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands.
RENB
US$0.14
7D
-13.0%
1Y
-70.6%
Xilio Therapeutics
Market Cap: US$39.3m
A clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies.
XLO
US$0.76
7D
-0.6%
1Y
1.0%
Generation Bio
Market Cap: US$38.8m
A biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells.
GBIO
US$5.72
7D
-4.3%
1Y
-75.3%
Jasper Therapeutics
Market Cap: US$37.9m
A clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.
JSPR
US$2.33
7D
-10.0%
1Y
-87.6%
Senti Biosciences
Market Cap: US$36.9m
A clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.
SNTI
US$1.40
7D
0.7%
1Y
-38.6%
Mural Oncology
Market Cap: US$36.2m
Operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer.
MURA
US$2.09
7D
0.5%
1Y
-31.0%
Akari Therapeutics
Market Cap: US$36.2m
An oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins.
AKTX
US$1.12
7D
40.0%
1Y
-63.3%
Bioqual
Market Cap: US$35.8m
Provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.
BIOQ
US$40.00
7D
8.1%
1Y
-40.7%
AN2 Therapeutics
Market Cap: US$34.8m
A biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.
ANTX
US$1.24
7D
-3.9%
1Y
17.5%
OnKure Therapeutics
Market Cap: US$34.4m
A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers.
OKUR
US$2.54
7D
2.4%
1Y
n/a
LakeShore Biopharma
Market Cap: US$33.0m
A biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer.
LSBC.F
US$0.73
7D
-7.6%
1Y
-90.6%
Revium Rx
Market Cap: US$31.6m
A pre-clinical stage biopharmaceutical company, develops nano-liposomal particles (NLP) based pharmaceutical candidates.
RVRC
US$0.52
7D
0%
1Y
73.3%
NeuroSense Therapeutics
Market Cap: US$29.6m
A clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally.
NRSN
US$1.18
7D
-2.5%
1Y
-7.1%
Kezar Life Sciences
Market Cap: US$27.8m
A clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States.
KZR
US$3.75
7D
-0.3%
1Y
-29.0%
Boundless Bio
Market Cap: US$25.6m
A clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA).
BOLD
US$1.13
7D
-0.9%
1Y
-67.9%
Enlivex Therapeutics
Market Cap: US$24.9m
Operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
ENLV
US$1.03
7D
-1.9%
1Y
-34.8%
Propanc Biopharma
Market Cap: US$24.8m
A development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia.
PPCB
US$1.81
7D
-17.4%
1Y
-89.9%
Passage Bio
Market Cap: US$24.5m
A genetic medicines company, develops gene therapies for central nervous system diseases.
PASG
US$7.68
7D
1.7%
1Y
-40.0%
SAB Biotherapeutics
Market Cap: US$22.5m
A clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders.
SABS
US$2.10
7D
-24.7%
1Y
-21.3%
Neuphoria Therapeutics
Market Cap: US$21.5m
A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.
NEUP
US$12.45
7D
32.4%
1Y
n/a
Cingulate
Market Cap: US$21.5m
A biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
CING
US$3.79
7D
7.7%
1Y
-26.3%
Curis
Market Cap: US$21.1m
A biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
CRIS
US$1.64
7D
-4.7%
1Y
-67.7%
Evaxion
Market Cap: US$20.8m
A clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.
EVAX
US$4.53
7D
50.0%
1Y
-70.4%
Allarity Therapeutics
Market Cap: US$20.8m
A clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs.
ALLR
US$1.54
7D
-2.5%
1Y
-30.9%
Citius Pharmaceuticals
Market Cap: US$20.2m
A biopharmaceutical company, focuses on the development and commercialization of critical care products.
CTXR
US$1.15
7D
-1.7%
1Y
-91.1%
Finch Therapeutics Group
Market Cap: US$20.1m
A clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
FNCH
US$12.58
7D
3.1%
1Y
14.4%
Harvard Bioscience
Market Cap: US$19.9m
Develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally.
HBIO
US$0.44
7D
-9.1%
1Y
-83.5%
Synlogic
Market Cap: US$19.9m
A biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.
SYBX
US$1.66
7D
-0.6%
1Y
8.5%
Aytu BioPharma
Market Cap: US$18.5m
A pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
AYTU
US$1.86
7D
-21.5%
1Y
-34.7%
Bionano Genomics
Market Cap: US$17.0m
Provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
BNGO
US$1.71
7D
-4.5%
1Y
-93.5%
Longeveron
Market Cap: US$16.8m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.79
7D
3.1%
1Y
-59.7%